ACM
CNTX icon

ADAR1 Capital Management’s Context Therapeutics CNTX Stock Holding History

ADAR1 Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Buy
750,969
+399,875
+114% +$811K 0.02% 221
2026
Q1 		$920K Hold
351,094
– – 0.05% 166
2025
Q4 		$516K Hold
351,094
– – 0.04% 182
2025
Q3 		$340K Hold
351,094
– – 0.03% 159
2025
Q2 		$230K Hold
351,094
– – 0.04% 152
2025
Q1 		$215K Hold
351,094
– – 0.04% 144
2024
Q4 		$369K Sell
351,094
-22,741
-6% -$39.4K 0.07% 125
2024
Q3 		$733K Sell
373,835
-271,326
-42% -$602K 0.12% 95
2024
Q2 		$1.29M Buy
645,161
+439,227
+213% +$757K 0.24% 57
2024
Q1 		$284K Buy
+205,934
New +$232K 0.06% 106

Other funds holding CNTX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

ADAR1 Capital Management's CNTX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Context Therapeutics (CNTX) stake by 114% in Q2 2026, buying an estimated $811K and bringing the position to 750,969 shares worth $416K. The position accounts for 0.02% of the portfolio, ranked #221.

ADAR1 Capital Management first reported a position in CNTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.29M in Q2 2024. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • ADAR1 Capital Management held 750,969 shares of Context Therapeutics worth $416K as of Q2 2026.
  • ADAR1 Capital Management bought 399,875 Context Therapeutics shares in Q2 2026, an estimated $811K.
  • Context Therapeutics made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #221 holding.
  • ADAR1 Capital Management first reported a position in Context Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • ADAR1 Capital Management's Context Therapeutics position peaked at $1.29M in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.